



April 26, 2000

Jim McCafferty
Director, Clinical Scientists
Clinical Research and Medical Affairs North America
SmithKline Beecham Pharmaceuticals UP 4410
1250 S Collegeville Rd
Collegeville, PA 19426

SCIENTIFIC THERAPEUTICS
INFORMATION, INC

505 Morris Avenue
Springfield, New Jersey
07081

(973) 376-5655 telephone
(973) 376-0611 fax 1
(973) 376-5567 fax 2

<http://www.stimedinfo.com>
E-mail: stati@stimedinfo.com

RE: REVISION OF PAROXETINE ADOLESCENT DEPRESSION MANUSCRIPT

Dear Jim:

After an unanticipated delay due to a shift in priority assignments for the Paxil account, I am enclosing the revised manuscript. This version reflects both the JAMA reviewer comments and the comments of several authors who responded to our strategy letter earlier in the year. I attempted to make as many of the JAMA reviewer comments as practical. A summary of the more substantive points is listed below:

1. A more thorough discussion of the high placebo response rate in the Conclusion section.
2. A 'study limitations' paragraph has been added to the Conclusion that addresses the fact that the study was not designed to directly compare paroxetine and imipramine; that the HAMD score at baseline was low relative to adult studies; and that patients with externalizing disorders were eligible for enrollment.
3. The mean imipramine plasma concentrations at weeks 4 and 8 will be stated (SB: please provide this data), and it is stated that a more thorough discussion of this data will appear in a separate publication.
4. A new figure (Fig 3) showing the HAMD total score response vs time.
5. As noted by several reviewers, the definitions of remission and response overlap. Boris Birmaher suggested that the definitions be revised to delete mention of remission and simply describe response. This suggestion is reflected in the enclosed manuscript.
6. As suggested by Reviewer #2, the title is revised to delete the phrase 'But Not Imipramine.'

After hearing back from yourself and the 3 lead authors, I will address your comments, circulate the revised draft to all authors for their approval and signed release forms for *American Journal of Psychiatry*, and prepare a submission package for Dr Keller.

Thank you for your attention to this matter, and I apologize once again for the extended delay in returning this manuscript to you.

Sincerely,

Sally K. Laden, MS
Associate Editorial Director

encl

cc: .1301

PAR000756969